Stockreport

Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC [Yahoo! Finance]

Cardiff Oncology, Inc.  (CRDF) 
PDF SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel t [Read more]